The avoiding late diagnosis of ovarian cancer (ALDO) project; a pilot national surveillance programme for women with pathogenic germline variants in BRCA1 and BRCA2

Conclusion
OC surveillance for women deferring RRSO in a ‘real-world’ setting is feasible and demonstrates similar performance to research trials; it down-stages OC, leading to a high complete cytoreduction rate and is cost-saving in the UK National Health Service (NHS) setting. While RRSO remains recommended management, ROCA-based surveillance may be considered for female BRCA-heterozygotes who are deferring such surgery.

Source: Journal of Medical Genetics - April 20, 2023 Category: Genetics & Stem Cells Authors: Philpott, S., Raikou, M., Manchanda, R., Lockley, M., Singh, N., Scott, M., Evans, D. G., Adlard, J., Ahmed, M., Edmondson, R., Woodward, E. R., Lamnisos, A., Balega, J., Brady, A. F., Sharma, A., Izatt, L., Kulkarni, A., Tripathi, V., Solomons, J. S., Ha Tags: Open access, Press releases Cancer genetics Source Type: research